ST105-01: UNBIASED IN-VIVO AND IN-SILICO TL-532 MECANISM OF ACTION BY RNA-SEQUENCING

Tollys characterized and patented a family of TLR3 proprietary ligands, including the drug candidate TL-532 considered in this study. The aim of this project is to use unbiassed high-throughput transcriptomic approach to decipher signaling pathways linked to the mechanisms of action of the drug candidate TL-532 (including induction of programmed death, immunological activation, TH1 and BDCA3 response, cytokines and chemokines expression, angiogenesis, infiltrates, etc.), induced early (3h, 6h and 24h post-treatment), after a single locoregional treatment, at a dose known to be very effective in this model. Tumor mRNA profiles of Mock treated or TL-532 treated mice were recovered after 3h, 6h and 24h post treatment respectively and generated by deep sequencing, in triplicate,